(Q34089126)

30 July 2017

1 reference

title

Angiogenesis and angiogenic mediators in haematological malignancies (English)

1 reference

30 July 2017

1 reference

Mangi MH

1

1 reference

30 July 2017

Newland AC

series ordinal

2

1 reference

30 July 2017

language of work or name

English

0 references

publication date

1 October 2000

1 reference

British Journal of Haematology

30 July 2017

published in

1 reference

30 July 2017

volume

111

1 reference

30 July 2017

issue

1

1 reference

30 July 2017

page(s)

43-51

1 reference

Isolation of putative progenitor endothelial cells for angiogenesis

30 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2000.02104.X

Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2000.02104.X

Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2000.02104.X

Requirement of vascular integrin alpha v beta 3 for angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2000.02104.X

Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2000.02104.X

The microcirculation of the bone marrow

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2000.02104.X

Blood vessel maturation: vascular development comes of age

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2000.02104.X

Seminars in Medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2000.02104.X

Angiogenesis in cancer, vascular, rheumatoid and other disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2000.02104.X

Blood vessel formation: what is its molecular basis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2000.02104.X

Induction of angiogenesis during the transition from hyperplasia to neoplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2000.02104.X

Unexpected pattern of beta-globin mutations in beta-thalassaemia patients from northern Portugal

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2000.02104.X

Cytokine regulation of endothelial cell function: from molecular level to the bedside

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2000.02104.X

Elevated levels of an angiogenic peptide, basic fibroblast growth factor, in the urine of patients with a wide spectrum of cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2000.02104.X

What is the role of vascular endothelial growth factor-related molecules in tumor angiogenesis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2000.02104.X

Endostatin: an endogenous inhibitor of angiogenesis and tumor growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2000.02104.X

Mechanisms of angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2000.02104.X

Vascular endothelial growth factors VEGF-B and VEGF-C are expressed in human tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2000.02104.X

Distinct roles of the receptor tyrosine kinases Tie-1 and Tie-2 in blood vessel formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2000.02104.X

Antitumor activity of thalidomide in refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2000.02104.X

Suppression of p53 activity and p21WAF1/CIP1 expression by vascular cell integrin alphaVbeta3 during angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2000.02104.X

Potentiation of cytotoxic cancer therapies by TNP-470 alone and with other anti-angiogenic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2000.02104.X

VEGFR-3 and its ligand VEGF-C are associated with angiogenesis in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2000.02104.X

Prospective study of intratumoral microvessel density, p53 expression and survival in colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2000.02104.X

Vascular dysmorphogenesis caused by an activating mutation in the receptor tyrosine kinase TIE2

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2000.02104.X

Vasculogenesis, angiogenesis, and growth factors: ephrins enter the fray at the border

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2000.02104.X

A cancer therapy resistant to resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2000.02104.X

10.1046/J.1365-2141.2000.02104.X

21 January 2018

Identifiers

DOI

1 reference

30 July 2017

1 reference